| Literature DB >> 32492023 |
Rachel P Chase1, Marko Kerac2, Angeline Grant3, Mark Manary4, André Briend5,6, Charles Opondo7, Jeanette Bailey2,8.
Abstract
BACKGROUND: Severe and moderate acute malnutrition (SAM and MAM) are currently treated with different food products in separate treatment programs. The development of a unified and simplified treatment protocol using a single food product aims to increase treatment program efficiency and effectiveness. This study, the first stage of the ComPAS trial, sought to assess rate of growth and energy requirements among children recovering from acute malnutrition in order to design a simplified, MUAC-based dosage protocol.Entities:
Year: 2020 PMID: 32492023 PMCID: PMC7269364 DOI: 10.1371/journal.pone.0230452
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow chart.
Sample description.
| Kenya | Pakistan | Chad | Yemen | S. Sudan | Total | |
|---|---|---|---|---|---|---|
| 439 | 1952 | 1422 | 483 | 1222 | 5518 | |
| … representing X visits | 2701 | 9052 | 10085 | 2916 | 9188 | 33942 |
| 6–11 months | 146 (33%) | 493 (25%) | 548 (39%) | 113 (23%) | 326 (27%) | 1626 (29%) |
| 12–23 months | 135 (31%) | 813 (42%) | 576 (41%) | 128 (27%) | 544 (45%) | 2196 (40%) |
| 24–35 months | 77 (18%) | 400 (20%) | 211 (15%) | 69 (14%) | 248 (20%) | 1005 (18%) |
| 36–59 months | 81 (18%) | 246 (13%) | 87 (6%) | 173 (36%) | 104 (9%) | 691 (13%) |
| Female | 226 (51%) | 1104 (57%) | 802 (56%) | 270 (56%) | 585 (48%) | 2987 (54%) |
| Male | 213 (49%) | 848 (43%) | 620 (44%) | 213 (44%) | 637 (52%) | 2531 (46%) |
| HAZ<-2 | 206 (47%) | 876 (45%) | 989 (70%) | 201 (42%) | 484 (40%) | 2756 (50%) |
| HAZ≥-2 | 226 (51%) | 370 (19%) | 429 (30%) | 281 (58%) | 731 (60%) | 2037 (37%) |
| Missing height | 7 (2%) | 706 (36%) | 4 (<1%) | 1 (<1%) | 7 (1%) | 725 (13%) |
| TFP | 121 (28%) | 276 (14%) | 386 (27%) | 116 (24%) | 1222 (100%) | 2121 (38%) |
| SFP | 318 (72%) | 1676 (86%) | 1036 (73%) | 367 (76%) | N/A | 3397 (62%) |
| Oedema = 0 | 239 (54%) | 1943 (>99%) | 1421 (>99%) | 483 (100%) | 3 (<1%) | 4089 (74%) |
| Missing | 200 (46%) | 8 (<1%) | 1 (<1%) | 0 (0%) | 1209 (99%) | 1418 (26%) |
| Oedema = 1,2,or 3 | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) | 10 (1%) | 11 (<1%) |
Fig 2Average daily proportional weight change (solid line) and weekly MUAC change (dashed line) vs MUAC at prior visit.
Fig 3Estimated daily energy (kcal) that would provide 95% of patient visits in the specified MUAC category with energy needs for observed growth.
Comparisons are made by: (A) MUAC category at admission, (B) continent, (C) and age group of 6–23 months (<24m) or 24–59 months (≥24m).
Fig 4Comparison of mean energy provided by each of five protocols: The protocol proposed herein, Golden’s minimum, intermediate, and standard protocols, the Sierra Leone protocol, and the Kenya protocol.
Estimated energy provided by proposed protocol as percentage of energy needed in observational data using 100 trials using subsamples of 200 visits from each of five countries (1000 visits total per simulated trial).
| Visits where MUAC < 115mm | Visits where 115mm ≤ MUAC < 125mm | |||||||
|---|---|---|---|---|---|---|---|---|
| Factor | Mean N (min-max) | Estimated median percentage of energy needs provided by proposed protocol | Mean percentage of visits with all energy requirements provided by protocol (Target: at least 95%) | Minimum and maximum value among subsamples | Mean N (min-max) | Estimated median percentage of energy needs provided by proposed protocol | Mean percentage of visits with half of energy requirements provided by protocol (Target: approx. 95%) | Minimum and maximum value among subsamples |
| Total | 199 (173–225) | 166% | 97% | 94%-100% | 801 (775–827) | 73% | 94% | 92%-95% |
| Sex | ||||||||
| Female | 125 (100–148) | 168% | 97% | 95%-100% | 432 (400–471) | 75% | 95% | 92%-97% |
| Male | 74 (59–94) | 161% | 96% | 89%-100% | 369 (331–401) | 71% | 92% | 88%-95% |
| Age (in months) | ||||||||
| 6 to 11 | 115 (92–138) | 175% | 98% | 95%-100% | 291 (265–335) | 83% | 98% | 97%-100% |
| 12 to 23 | 67 (49–89) | 159% | 96% | 87%-100% | 315 (270–349) | 72% | 96% | 93%-98% |
| 24 to 59 | 17 (8–29) | 133% | 90% | 72%-100% | 191 (156–220) | 60% | 83% | 77%-88% |
| Weight | ||||||||
| 3.5 to 5.9 | 86 (63–109) | 183% | 99% | 95%-100% | 103 (78–130) | 91% | 99% | 97%-100% |
| 6.0 to 7.9 | 106 (85–126) | 157% | 96% | 90%-100% | 470 (435–514) | 77% | 97% | 95%-99% |
| 8.0 to 17.5 | 8 (2–14) | 123% | 83% | 50%-100% | 228 (189–263) | 61% | 84% | 79%-90% |
| Admission type | ||||||||
| SFP | See note | 453 (426–485) | 74% | 95% | 93%-97% | |||
| TFP | 195 (164–222) | 166% | 97% | 94%-100% | 347 (313–378) | 72% | 91% | 88%-94% |
| Continent | ||||||||
| Asia | 59 (41–72) | 171% | 99% | 95%-100% | 341 (328–359) | 71% | 94% | 91%-96% |
| Africa | 140 (116–162) | 163% | 96% | 92%- 99% | 460 (438–484) | 75% | 93% | 90%-96% |
*Among eligible patients, children who were admitted to SFP facilities seldom had MUAC below 115mm during treatment and therefore performance based on TFP vs SFP admission among children with the lowest MUACs could not be compared.